A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR

Keyphrases

• Pancreatic Ductal Adenocarcinoma 100%
• Bcl-xL 100%
• Novel Regimens 100%
• Triplet 60%
• Afatinib 60%
• Doublet 60%
• Triplet Regimen 60%
• Trametinib 40%
• Cell Death 20%
• AKT1 20%
• Cytotoxicity 20%
• Glycogen Synthase Kinase 3 (GSK3) 20%
• Imaging Systems 20%
• Treatment Strategy 20%
• MEK Inhibitor (MEKi) 20%
• Therapeutic Efficacy 20%
• Treatment Group 20%
• P38 Mitogen-activated Protein Kinase (p38 MAPK) 20%
• Clinical Assessment 20%
• Patient-derived Xenograft 20%
• Cell Growth 20%
• Patient Response 20%
• Path Analysis 20%
• Multiplex 20%
• EGFR Signaling 20%
• Patient-derived 20%
• Solid Cancer 20%
• P70S6K 20%
• EGFR Inhibitors 20%
• Tumor Growth Rate 20%
• Live Cell Imaging 20%
• Combinational Therapy 20%
• Pancreatic Duct Cells 20%
• Degrader 20%
• In Vitro Comparison 20%
• Immune Assay 20%
• Combinational 20%
• KRAS Signaling 20%
• Activation Network 20%
• Suppressing Cell 20%
• Target Pathways 20%
• EGFR Inhibition 20%
• Therapeutic Safety 20%
• In Vivo murine Model 20%
• P90RSK 20%

Medicine and Dentistry

• Pancreas Adenocarcinoma 100%
• Epidermal Growth Factor Receptor 100%
• Afatinib 60%
• Trametinib 40%
• Cell Death 20%
• Cancer 20%
• Carcinogenesis 20%
• Tumor Progression 20%
• Combination Therapy 20%
• In Vitro 20%
• Xenograft 20%
• Cytotoxicity 20%
• Cell Line 20%
• Protein Kinase B 20%
• Immunoassay 20%
• Clinical Assessment 20%
• Cell Growth 20%
• EGFR Inhibitors 20%
• MEK Inhibitor 20%
• p38 Mitogen-Activated Protein Kinase 20%
• Live Cell Imaging 20%
• Treatment Group 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Pancreas Adenocarcinoma 100%
• Afatinib 60%
• Trametinib 40%
• Combination Therapy 20%
• Tumor Growth 20%
• Carcinogenesis 20%
• Protein Kinase B 20%
• Mitogen Activated Protein Kinase Kinase Inhibitor 20%
• Cellular Imaging 20%
• Cytotoxicity 20%
• Treatment Group 20%